The market is fully liberalized, and a large number of traditional Chinese medicine companies are stepping up their deployment in the field of traditional Chinese medicine formula particles

 According to a joint document issued by the State Food and Drug Administration, the Administration of Traditional Chinese Medicine, the Health Commission, and the Medical Insurance Administration, all qualified Chinese medicine companies only need to file for records to produce Chinese medicine formula granules starting from November 1
.
With the full liberalization of the market, the Chinese medicine formula granule industry will usher in a broad market space
.
In this context, many Chinese medicine companies are stepping up their deployment
.
Shineway Pharmaceuticals Shineway Pharmaceuticals is actively welcoming the upcoming "spring" of the development of traditional Chinese medicine formula granules.
On the one hand, it accelerates the preparation of the national standard of formula granules, on the other hand, it expands the production capacity of Chinese medicine formula granules and accelerates the expansion of the sales team to promote traditional Chinese medicine.
Formulation particle development
.
Regarding traditional Chinese medicine formula granules, Shenwei Pharmaceutical relies on modern Chinese medicine intelligent manufacturing technology to apply the total quality control system of Chinese medicine injection to the research and development and production of Chinese medicine formula granules, and has established a production process covering more than 700 commonly used Chinese medicine formula granules.
, Quality control system and quality standards, promote the standardization of traditional Chinese medicine formula granules
.
Currently, Shenwei Pharmaceutical has invested more than 1 billion yuan in research on the preparation process and quality standards, pharmacodynamics and clinical application of Chinese medicine formula granules, and has achieved significant results
.
Yibai Pharmaceuticals Yibai Pharmaceuticals actively deploys the Chinese medicine formula granule industry
.
In November 2019, the company passed the GMP certification of traditional Chinese medicine decoction pieces and has a complete production capacity of traditional Chinese medicine decoction pieces and traditional Chinese medicine formula granules; in February 2020, the company obtained the pilot qualification of traditional Chinese medicine formula granules in Guizhou Province; June 29, 2020, the company announced " "White Peony Formula Granules" and other 124 varieties have been approved for clinical research; on September 23, the company announced that another 165 varieties of "Banlangen Formula Granules" and other 165 varieties have been approved for clinical trials, with a total of 289 varieties
.
Based on the advantages of the entire industry chain layout, Yibai Pharmaceutical is constantly developing distinctive Chinese medicine varieties and developing various Chinese medicine formula particles with the help of the platform of the Miao Medicine Engineering Center
.
According to reports, traditional Chinese medicine formula granules can help enrich the company’s pharmaceutical product matrix, and as an emerging medical product, Chinese medicine formula granules have high technical and qualification barriers.
They are a manifestation of the company’s overall R&D and innovation capabilities.
Performance and brand image are all promoting
.
Zhenbaodao Pharmaceuticals With the end of the trial, the Chinese medicine formula granule market will be reshuffled, and Zhenbaodao Pharmaceuticals will embrace the tens of billions of blue ocean market for Chinese medicine formula granules
.
It is understood that Zhenbaodao Pharmaceutical has successfully filed 550 formula granules of commonly used Chinese medicines and obtained market access
.
Actively participate in the research and formulation of national standards and provincial standards for formula particles to ensure that the formula particles of Zhenbaodao Pharmaceutical have strong competitiveness and market advantages in terms of quality and efficacy
.
The company has successively carried out research on formula granules with Zhejiang University, Peking University and other scientific research institutions.
In the core areas of formula granule production, quality control, process exploration, etc.
, a large number of scientific research results have been achieved, laying a solid foundation for formula granule production and research
.
Hongri Pharmaceuticals, as one of the earliest companies that produced TCM formula granules, has more than 600 types of granular products, which basically cover all the varieties with high frequency of clinical use of TCM.
It is basically in terms of product types, production processes, quality control, etc.
Formed a barrier advantage
.
In June of this year, Hongri Pharmaceutical invested 750 million yuan to build a local intelligent manufacturing base of traditional Chinese medicine formula particles.
After the completion of the project, the annual sales scale is expected to exceed 3 billion yuan
.
It is reported that this is the eighth Chinese medicine formula granule production base continuously constructed by Hongri Pharmaceutical in China
.
According to the industry, the direct reason for Hongri Pharmaceutical's "batch" investment in building a factory to produce formula particles is that the country has tried 27 years of policy on the pilot work of Chinese medicine formula particles, which was terminated on November 1 this year
.
Chinese medicine formula granules refer to a pure Chinese medicine type with uniform specifications and quality standards that are processed through extraction, concentration, granulation and other technologies using traditional Chinese medicine decoction pieces as raw materials
.
According to data from the Ministry of Industry and Information Technology, the market size of Chinese medicine formula granules in 2019 is about 50.
3 billion yuan, and in 2020 it is about 53.
3 billion yuan
.
The industry said that with the implementation of favorable policies, the liberalization of the market, and the release of potential, the Chinese medicine formula granule industry will form a market of 100 billion yuan.
Now a large number of Chinese medicine companies are actively deploying and seizing this market
.